Study objectives: The aim of this study was to describe our experience at one institution with pulmonary veno-occlusive disease (PVOD) during the past 10 years, with particular reference to new findings and long-term outcome. Setting: Tertiary care, academic medical center. Patients and methods: Eleven patients who were evaluated and treated for PVOD at our institution were retrospectively studied. Included were all available clinical, radiographic, hemodynamic, and pathologic data. Results: All 11 patients in our series had at least one symptom or clinical finding that, in conjunction with known pulmonary hypertension, suggested the diagnosis of PVOD. Digital clubbing, not previously reported in PVOD, was found in 5 patients, rales in 6, and increased interstitial markings on chest radiograph in 10. Half of the 10 patients who underwent acute vasodilator testing exhibited a decrease in pulmonary artery pressure of > 20%, although one patient died shortly after receiving IV calcium-channel blockers. Three patients have demonstrated sustained clinical improvement with therapy, which includes calcium-channel blockers, epoprostenol, and lung transplantation in one patient each. However, outcome was generally poor, with a 72% mortality within 1 year of diagnosis. Conclusion: The diagnosis of PVOD requires a high clinical suspicion. However, both physical examination findings and radiographic studies often provide clues to the diagnosis, which may obviate the need for lung biopsy in the majority of cases. Although there may be patients who respond to medical therapy, the use of vasoactive medications in patients with PVOD should be undertaken with great caution. Long-term survival is poor, and lung transplantation remains the only proven therapy.
P
ulmonary veno-occlusive disease (PVOD) is an uncommon variant of primary pulmonary hypertension (PPH) that preferentially affects the postcapillary pulmonary vasculature and often poses diagnostic and management dilemmas. Symptomatically, patients with PVOD frequently present in a similar fashion to other forms of pulmonary hypertension (PHTN). However, this report will emphasize distinct clinical, radiographic, and hemodynamic findings that can provide clues to the diagnosis of PVOD.
The disease was first described by Hora 1 in 1934 and, on the basis of its similarities to hepatic venoocclusive disease, was termed PVOD by Heath et al 2 in 1966. The term pulmonary vaso-occlusive disease has been suggested by others, as additional pathologic evidence has demonstrated arterial as well as venous changes. 3 However, there is a general consensus that the primary pathologic changes occur in the venous circulation, making the term PVOD more reflective of the primary disease process.
In the first 50 years after its original description, only 67 cases were reported. 3 Since that time, the total number of cases reported has increased, with approximately 150 cases now reported in the literature. Greater awareness of the condition likely ac-counts for the increase in the number of reported cases in recent years, as there is no evidence that there is an increase in the overall incidence of the disease.
Epidemiologically, PVOD affects all age groups and has been reported all over the world without geographic predilection. The youngest reported case was in a 9-day-old neonate, and the oldest in a 67-year-old man, although the majority of affected patients are Ͻ 50 years old. In the pediatric population, both sexes are equally affected. In the adult population, the ratio of male to female patients is approximately 2:1. 4 During the past 10 years, we have encountered 11 patients with PVOD at our institution, which represents the largest case series of PVOD to date (and to our knowledge). Although some of the findings seen in our patients have been noted previously, we report additional features of PVOD that have not been described in the literature. Therapy commonly used to treat patients with PPH, such as calciumchannel blockers (CCBs) or epoprostenol (PGI 2 ), can lead to disastrous outcomes in patients with PVOD. 5 Therefore, our observations may aid in the diagnosis and management of this disease. Last, we review the literature on PVOD and summarize the salient features that have been reported.
Materials and Methods
The medical records of 11 patients with PVOD evaluated at our institution were reviewed. Entire records were searched based on data originally obtained from shadow charts filed at the Center for Lung Research under the file title "PVOD patients." All 11 patients had received International Classification of Diseases, Ninth Revision code 416.0, titled "Primary Pulmonary Hypertension." Ten patients were evaluated and received diagnoses at our center, whereas one patient was referred to us with the preliminary diagnosis of PPH and subsequently received a diagnosis of PVOD. One patient, who had right heart catheterization results suggestive of PVOD, was excluded from the review owing to a lack of any other clinical or radiographic data consistent with PVOD. Clinical history, physical examination, laboratory data, and radiographic studies were all included in our analysis. Baseline hemodynamic data, obtained using the standard cardiac catheterization protocol for Vanderbilt University Medical Center, were available on all patients, including the responses to short-term vasodilator testing in 10 patients. Nine of the 11 patients had direct tissue examination confirming PVOD, either by open lung biopsy or at autopsy. In one patient, PVOD was diagnosed by open lung biopsy specimen and confirmed in the native lung at the time of unilateral lung transplantation. The two patients reported who did not have tissue available for direct examination demonstrated overwhelming clinical, radiographic, and hemodynamic evidence of PVOD.
Results

History and Physical Findings
Demographic features and outcomes of our patients are shown in Table 1 . The ratio of men to women was 1:1.2. The mean age of the patients studied was 39 years (range, 9 to 59 years). Pertinent signs and symptoms in our patients are shown in Table 2 . At the time of presentation, 7 of 11 patients were in New York Heart Association (NYHA) class III, and 4 patients were in NYHA class IV. Mean duration of symptoms before presenting for evaluation was 18 months (range, 1 month to 3 years). All 11 patients reported progressive dyspnea. Six patients noted a nonproductive cough, and four patients experienced a viral-like syndrome before the development of progressive dyspnea and cough. Both orthopnea and paroxysmal nocturnal dyspnea were present in two patients. Other less common complaints included atypical chest pain and nearsyncope, as well as increased wheezing in two patients with a history of reactive airways disease. Physical examination demonstrated a prominent P2 component of the second heart sound and a tricuspid regurgitation murmur in all 11 patients. Signs of overt cor pulmonale, including jugular venous distention, a third heart sound, a right ventricular heave, and lower extremity edema were noted in seven patients at time of presentation. Three of the 11 patients also demonstrated peripheral cyanosis.
Findings suggestive of a diagnosis other than PPH were also observed. Six of 11 patients had bibasilar rales on chest auscultation, and four of these six were also noted to have digital clubbing. One other patient had clubbing but no rales on examination ( Table 2) .
Laboratory Data
The measurement of room air arterial blood gases revealed varying degrees of hypoxemia and a widened alveolar-arterial oxygen pressure difference in all patients (Table 3) . Serologic studies were performed in all 11 patients and revealed a weakly positive antinuclear antibody titer of 1:160 in two patients. All other markers of connective tissue disease were negative, including antiphospholipid antibodies. Pulmonary function tests demonstrated mild obstruction in three patients, mild restriction in two patients, combined obstruction and restriction in two patients, and normal spirometry and lung volumes in four patients. Nine of 11 patients showed a decrease in the diffusing capacity of the lung for carbon monoxide (Dlco), and 6 patients had severe reductions to Ͻ 50% of predicted. Linear regression analysis failed to demonstrate any correlation between the reductions in Dlco and reductions in total lung capacity or spirometry.
Radiographic Findings
Radiographic findings (Table 4 ) aided greatly in establishing the diagnosis of PVOD. Chest radiographs revealed enlarged proximal pulmonary arteries (PAs) in all 11 patients, mild-to-moderate peripheral interstitial infiltrates or septal lines in 10 patients, and right-sided pleural effusions in 4 patients (Fig 1) . No patient had evidence of left ventricular or left atrial enlargement. CT of the chest was performed in nine patients. Six patients had bilateral smooth intralobular septal thickening. A ground-glass mosaic-attenuation pattern, believed to represent varying regions of underperfusion and interstitial edema, was seen predominantly in the lower lobes in six patients (Fig 2) . Three of the nine patients had evidence of mediastinal and perihilar lymphadenopathy, and two had small pericardial effusions. Ventilation-perfusion (V /Q ) scans were performed in 10 patients. Six demonstrated normal perfusion, and four showed small, inhomogenous subsegmental matched or mismatched defects consistent with a low probability for pulmonary embolism. One patient with a segmental perfusion defect underwent a pulmonary angiogram, which did not demonstrate evidence of thromboembolic disease.
Hemodynamic Data
Right heart catheterization was performed in all 11 patients during initial diagnostic evaluation, and 10 of the 11 underwent short-term vasodilator testing (Table 5 ). Five patients received inhaled nitric oxide at 20 to 40 ppm, two received escalating doses of IV nicardipine starting at 2 mg/h, and two received both vasodilators. One patient underwent short-term vasodilator testing with epoprostenol (PGI 2 ), starting at a dose of 2 ng/kg/min. For the 11 patients, the mean (Ϯ SD) PA pressure was 65 Ϯ 16 mm Hg, cardiac output was 3.9 Ϯ 1.2 L/min, and pulmonary vascular resistance was 15.5 Ϯ 6.5 U. Mixed venous saturation averaged 57 Ϯ 13.7%. Pulmonary arterial occlusion pressure (PAOP) was 11 Ϯ 3 mm Hg. One patient demonstrated an 11 mm Hg difference between balloon occlusion and catheter tip-occlusion measurements obtained in the left mid-lung zone, although balloon-wedge measurements taken in multiple lung zones in this patient did not vary Ͼ 1 to 2 mm Hg. Left-sided pressures and valve gradients were normal in the patients studied. Of the 10 patients who underwent short-term vasodilator testing, 8 responded favorably, with an average decrease in mean PA pressure of 22 Ϯ 15%. One patient demonstrated no change, and one patient had a 47% increase in mean pressure associated with the development of overwhelming pulmonary edema.
Pathology
Biopsy or autopsy tissue was available for histopathologic examination in nine patients and confirmed the diagnosis of PVOD. None had evidence of plexiform lesions, and Movat stain confirmed primary venous-based lesions. Seven had evidence of secondary arteriolar medial hypertrophy and intimal proliferation, seven had alveolar hemorrhage and hemosiderosis, and one had evidence of interstitial mononuclear infiltrates (Figs 3, 4) . All bacterial, fungal, and viral stains were negative. All nine patients had evidence of secondary organized arterial and venous thromboses, which were confined to the precapillary and postcapillary microcirculation.
Treatment and Outcome Data
Pulmonary edema developed with the use of CCBs in six patients, although only one episode occurred during acute testing. This patient experienced acute pulmonary edema at a dose of 10 mg/h of IV nicardipine, and subsequently died 2 h after developing pulseless electrical activity. The other five experienced pulmonary edema during long-term treatment with oral therapy. This occurred as early as 3 days and as late as 6 months after starting CCB therapy. One patient died of complications from pneumonia 5 months after starting CCB therapy. The type or dose of CCB did not correlate with the development of pulmonary edema. None of the patients treated with CCBs were able to tolerate the large doses advocated in treatment of patients with PPH. 6, 7 One patient has been maintained on a regimen of CCB therapy for 2 years with sustained clinical improvement. Interestingly, this patient experienced mild pulmonary edema when extendedrelease nifedipine was increased to 60 mg bid. This resolved with a 50% reduction in dose. Three patients were treated with IV PGI 2 . One patient died of worsening right heart failure, without evidence of pulmonary edema, 3 days after starting therapy. Another patient died suddenly at home 6 months after beginning treatment. However, another patient tolerated short-term vasodilator testing with PGI 2 and continues to receive treatment at a dose of 13 ng/kg/min, nearly 2 years after diagnosis.
Mortality in our cohort was high. Eight of the 11 patients died within 1 year of diagnosis. However, three patients have had significant clinical improvement with therapy. As noted above, marked improvement has occurred in one patient receiving oral CCB and in another receiving PGI 2 . A third patient underwent successful single-lung transplantation in 1990 and is alive and well 9 years later. Symptom severity in all three patients has improved from NYHA class III or IV to class I or II.
Discussion PVOD is a rare form of PPH that has been reported in the literature as isolated case reports, small series of fewer than five patients, or compilations of previous case studies. Findings in our 11 patients confirm some previously reported findings, but we have made several new observations. Our male-to-female ratio of 1:1.2 differs somewhat from previous reports. However, the age range in our patient population is consistent with earlier studies, with a 50-year span between our youngest patient of 9 years and our oldest of 59 years. Every patient in this series had one or more distinguishing clinical feature suggesting the diagnosis of PVOD. The primary pathologic changes in PVOD occur in the postcapillary vascular bed. Thus, signs and symptoms indicative of pulmonary capillary hypertension were common in our series. Six of the 11 patients had coarse, bibasilar rales, and two reported orthopnea and paroxysmal nocturnal dyspnea.
Nearly 50% of our patients were found to have digital clubbing on physical examination, a finding that has not been reported in association with PVOD. Clubbing is seen in a variety of chronic lung diseases, including interstitial lung disease. Only one patient with clubbing in our study was shown to have interstitial inflammation in addition to pulmonary venous changes on lung biopsy specimen, making it unlikely that clubbing was a manifestation of interstitial lung disease in these patients. Although the mechanisms of clubbing are still unknown, some authors have proposed an intrapulmonary shunt from bronchial circulation anastomoses, resulting in megakaryocyte or platelet deposition in the nail beds and release of growth factors such as platelet-derived growth factor. 8,9 PPH has not been associated with clubbing, although there is ample histopathologic evidence that there is significant loss of the pulmonary vascular bed that could result in bronchial circulation anastomoses.
Pulmonary function testing can also provide a clue to the diagnosis. Elliot et al 10 reported a severe reduction in Dlco with normal spirometry and lung volumes in a patient with PVOD. Others have reported a restrictive defect in lung volumes in addition to a severe reduction in Dlco. In concurrence with these reports, we found a severe reduction in Dlco in Ͼ 50% of our patients. Although four of these patients also had mild restrictive defects, all had other clinical evidence suggestive of PVOD and biopsy specimens confirming the diagnosis.
Radiographic studies of patients with PVOD have received considerable attention in an effort to identify diagnostic features. Evidence of pulmonary venous hypertension is frequently present on plain chest films, including septal lines, mild-to-moderate basilar reticular interstitial infiltrates, and pleural effusions. Chest CT can be a valuable tool in establishing the diagnosis. Swenson et al 11 reviewed CT findings on eight PVOD patients and found that smooth interlobular septal thickening, multifocal ground-glass opacities, pleural effusions, and enlarged central PAs were commonly seen and were highly suggestive of PVOD.
A mosaic-attenuation pattern was also seen in a large percentage of patients, but in another study, this finding was nonspecific in the absence of other abnormalities. 12 All 11 patients demonstrated at least one of these radiographic abnormalities. More than 90% had chest radiographic findings suggestive of PVOD, and Ͼ 50% had one or more chest CT findings described above. V /Q scans, although useful for excluding thromboembolic disease, were often nonspecific and not helpful in making the diagnosis. Although one study has suggested that a segmental contour pattern on perfusion scanning may be indicative of PVOD, 13 this has not been reported by other investigators and was not noted in our patients.
Hemodynamic findings in PVOD have been examined in some detail. At one time, the triad of moderate-to-severe PHTN, radiographic evidence of pulmonary edema, and normal PAOP was thought to be diagnostic of PVOD. However, as more cases were reported, it became apparent that elevated PAOP can occur in this disease. As described by Harris and Heath, 14 the measured PAOP may be elevated or normal in PVOD, depending on the size of the veins involved and the degree of collateral communication between affected venous beds. All but one of our patients had PAOPs Յ 18 mm Hg. The only elevated PAOP observed was a catheter tip wedge pressure, which was considerably higher than the balloon wedge pressure obtained in the same vascular segment (23 vs 12 mm Hg).
Hemodynamic findings can help support the diagnosis of PVOD in conjunction with other suggestive clinical and radiographic data. Together, these findings can obviate the need for tissue diagnosis. In our series, we found that all nine of the patients who had biopsy specimen-proven or autopsy-proven PVOD demonstrated at least one physical or radiographic finding strongly suggestive of the diagnosis.
Histologically, PVOD most strikingly consists of eccentric intimal fibrosis of the small postcapillary pulmonary veins. However, medium-sized and large veins may be affected as well. A large proportion of the veins are typically involved when examined histologically, with Ͼ 75% of all veins affected in some cases. Intimal thickening consists of loose, paucicellular connective tissue. As the disease progresses, it is believed that obliterative fibrosis and occasional thrombosis with recanalization occur. The venous media thickens and forms multiple elastic laminae, a phenomenon called arterialization. The muscular PAs undergo secondary medial hypertrophy as well as occasional intimal fibrosis. Plexiform lesions are not seen, and if observed, suggest a primary arterial process. 15 A key pathologic feature of PVOD is the absence of normal veins on biopsy specimen, which often requires specific staining techniques. We have found that the Movat elastin stain, which can delineate internal and external elastic laminae, is essential to determine whether the affected vessels are arterial or venous. Because the changes in small veins cause them to resemble arteries, the only features specific for PVOD by hematoxylin-eosin staining may be the absence of normal-appearing small veins, a feature that can easily be overlooked. We found that, in many of our patients, the diagnosis of PVOD could not be made with certainty using the standard hematoxylin-eosin stain, and the Movat stain proved invaluable in making the diagnosis. In fact, three of our patients who were originally diagnosed as having PPH were diagnosed as having PVOD after examination of a Movat stain.
Treatment of PVOD poses a particular problem. Vasodilator therapy can be harmful and occasionally fatal in PVOD. Fulminant pulmonary edema has been reported with the use of PGI 2 . 16 Others have reported patients who initially responded to vasodilators, but eventually had progression of disease over a period of months. 17 To our knowledge there is only one case report describing long-term improvement with CCB therapy. 18 Other forms of therapy, including immunosuppressive and anti-inflammatory regimens, have been attempted but have shown little promise. 19, 20 Currently, lung transplantation is the only proven effective treatment of PVOD.
Our study has found a similar mix of responses. One patient experienced acute pulmonary edema with IV CCB testing, whereas others initially responded but then experienced edema with increases in the CCB dose over weeks to months. Despite the ability of some patients to tolerate CCB, these agents may provoke overwhelming pulmonary edema if selective precapillary vasodilation occurs, and we now avoid short-term vasodilator testing with CCB if PVOD is suspected. Based on these results, future treatment of PVOD with CCB or PGI 2 should be approached cautiously only by investigators with extensive experience in the evaluation and management of PHTN.
The cause or causes of PVOD remain unclear, although its association with multiple conditions has been reported. Based on previous histopathologic findings, some authors have proposed a viral origin, including HIV. 4, 21, 22 Other investigators have proposed an immunologic mechanism, based on evidence of immune complex deposition in a biopsy specimen obtained from a patient with PVOD. 23 The disease has also been reported in patients with collagen vascular disease, including systemic lupus erythematosus and CREST (calcinosis, Raynaud's syndrome, esophageal dysmotility, sclerodactyly, telangectasia) syndrome. 24, 25 Hematologic malignancies, as well as treatments directed at those disorders, have received considerable attention as a potential cause of PVOD. Multiple cases have been reported after both autologous and allogenic bone marrow transplantation. 26, 27 Radiation therapy has been associated with the development of PVOD months to years after treatment, and chemotherapeutic agents, such as 1,3-bis(2-chloroethyl)-1-nitrosourea (carmustine), bleomycin, and mitomycin, have been associated with the disease. 28, 29 Conclusion PVOD is a rare variant of PPH that often poses a diagnostic and therapeutic dilemma. However, there are nearly always clinical signs and symptoms to alert the clinician of its presence. Findings reported in our study specific for the disease included clubbing, pulmonary rales, and radiographic evidence of pulmonary venous hypertension in the absence of leftsided heart failure or valvular disease. PHTN in the setting of a severely decreased Dlco, as well as findings on chest radiograph and CT scan consistent with PVOD, should also prompt consideration of the diagnosis. Right-heart catheterization, although clinically useful, cannot definitively confirm the presence of PVOD. If biopsy tissue is available, special staining techniques, such as the Movat elastin stain, are usually necessary. However, the majority of the patients exhibit clinical evidence of the disease that can obviate the need for biopsy. Short-term vasodilator testing and treatment carry a higher risk of an adverse outcome than with conventional PPH and should be undertaken with caution by clinicians with extensive experience with PHTN. Transplantation remains the sole curative therapy for the disease, although it too is not without the potential for severe complications.
